Articles tagged "Renal function"

2016 American Transplant Congress
AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.
J. O'Leary,¹ A. Philippe,² H. Heidecke,² R. Freeman,¹ L. Jennings,¹ R. Catar,² G. Klintmalm,¹ D. Dragun.²
¹Baylor Simmons Transplant Insttute, Baylor University Medical Center, Dallas, TX; ²Internal Medicine, Charite, Berlin, Germany.
Angiotensin II Type-1 Receptor (AT1R) antibodies have been associated with pulmonary hypertension, renal allograft loss, and fibrosis progression in liver allograft recipients especially if combined…
2016 American Transplant Congress
Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.
J. Cruzado, H. Holdaas, P. Lopez, J. Aguilar, G. Dong, F. Claas, W. Arns, M. van der Giet, J. de Fijter.
ELEVATE study group, Llobregat Catalunya, Spain.
Background: Human leukocyte antigen (HLA) compatibility between donor and recipient is considered an important factor for graft outcomes. Compatibility is associated with a lower incidence…
2016 American Transplant Congress
Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.
P. Bernhardt,¹ G. Dong,² P. Lopez,¹ G. Hustache,¹ G. Bader.¹
¹Novartis Pharma AG, Basel, Switzerland; ²Novartis Pharmaceuticals Corporation, East Hannover.
Purpose:Cardiovascular disease (CVD) is one of the leading causes of death in liver transplant recipients (LTxRs). Impaired glomerular filtration rate (GFR) is a risk factor…
2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
J. Klepacki,¹ J. Klawitter,¹ J. Klawitter,¹ A. Karimpour-fard,² E. Anderson,¹ G. Ingle,³ D. Patel,³ K. Johnson,⁴ D. Cibrik,⁴ U. Christians.¹
¹University of Colorado Denver, Aurora, CO; ²University of Colorado Denver, Aurora, CO; ³Novartis Pharmaceuticals, East Hannover, NJ; ⁴University of Michigan, Ann Arbor, MI.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…
2016 American Transplant Congress
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.
J. de Fijter,¹ H. Holdaas,¹ M. Seelen,¹ S. Sundar,¹ F. Bemelman,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ M. van der Giet.¹
¹ELEVATE study group, Leiden, Netherlands; ²Novartis, Basel, Switzerland; ³Novartis Pharmaceutical Corporation, East Hanover, NJ.
Background: Proteinuria is a biomarker which helps in predicting graft outcomes in kidney transplant recipients (KTxRs). The ELEVATE study was designed to determine whether an…
2016 American Transplant Congress
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.
O. Serrano,¹ R. Kandaswamy,¹ K. Gillingham,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ H. Ibrahim,² A. Kukla,² R. Spong,² N. Issa,² T. Pruett,¹ A. Matas.¹
¹Surgery, University of Minnesota, Minneapolis, MN; ²Medicine, University of Minnesota, Minneapolis, MN.
PURPOSE: RDP after KTx is associated with increased early rejection; no decrease in medium‐term patient (PS) or graft survival (GS); and significantly decreased prednisone‐related side…
2016 American Transplant Congress
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.
G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli, F. Citterio.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction. Recent clinical trials have shown that the combination of CNIs with Everolimus (EVE) allows CNIs minimization, which may positively impact on chronic nephrotoxicity. Aim…
2016 American Transplant Congress
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.
J. de Fijter, H. Holdaas, P. Lopez, P. Bernhardt, D. Gaohong, J. Cruzado, M. van der Giet.
ELEVATE study group, Leiden, Netherlands.
Background: Several studies reported that recipients receiving renal allograft from living donors have better efficacy outcomes than the deceased donor counterparts. This post-hoc analysis of…
2016 American Transplant Congress
Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA).
A. Brigido, H. Tedesco, C. Felipe, M. Cristelli, M. Franco, J. Medina-Pestana.
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with EVR…
2016 American Transplant Congress
Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.
J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, E. Kwon, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim, C.-D. Kim.
Internal Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Objectives: There are few studies that compare the effect of different dose of tacrolimus after kidney transplantation. We investigated transplant outcome of low-dose and standard-dose…